Aytu Bioscience (NASDAQ:AYTU) posted its quarterly earnings data on Thursday. The company reported ($0.32) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.01, Fidelity Earnings reports. Aytu Bioscience had a negative net margin of 184.35% and a negative return on equity of 81.04%.
NASDAQ AYTU opened at $1.38 on Friday. Aytu Bioscience has a 12 month low of $0.68 and a 12 month high of $4.00. The company has a debt-to-equity ratio of 0.32, a current ratio of 4.10 and a quick ratio of 3.76. The firm has a market capitalization of $23.66 million, a PE ratio of -0.05 and a beta of 4.65. The company’s 50 day simple moving average is $1.38 and its 200 day simple moving average is $1.71.
AYTU has been the topic of a number of research analyst reports. LADENBURG THALM/SH SH raised their price objective on shares of Aytu Bioscience from $4.00 to $4.75 in a research note on Wednesday, September 18th. Zacks Investment Research lowered shares of Aytu Bioscience from a “buy” rating to a “hold” rating in a research note on Friday, August 2nd. Northland Securities set a $10.00 price objective on shares of Aytu Bioscience and gave the company a “buy” rating in a research note on Friday, September 13th. Finally, ValuEngine upgraded shares of Aytu Bioscience from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st.
Aytu BioScience, Inc, a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia.
Featured Article: Technical Indicators – What is a Golden Cross?
Receive News & Ratings for Aytu Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.